Review





Similar Products

phospho p38 mapk thr180 tyr182 rabbit mab  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc phospho p38 mapk thr180 tyr182 rabbit mab
Phospho P38 Mapk Thr180 Tyr182 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho p38 mapk thr180 tyr182 rabbit mab/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
phospho p38 mapk thr180 tyr182 rabbit mab - by Bioz Stars, 2024-10
86/100 stars
  Buy from Supplier
anti phospho p38 mapk thr180 tyr182 3d7 rabbit monoclonal antibody  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc anti phospho p38 mapk thr180 tyr182 3d7 rabbit monoclonal antibody
CXCL8 mRNA expression and IL-8 production by P. intermedia supernatants might be induced through transduction via ERK 1/2. ( A ) Inhibition of CXCL8 mRNA expression with dimethyl sulfoxide, Trametinib, Adezmapimod, SP600125, and caffeic acid phenethyl ester at a concentration of 10 μM was analyzed using real-time RT-PCR post 4 h incubation ( n = 4). ( B ) CXCL8 mRNA expression was inhibited by Trametinib pretreatment in a concentration-dependent manner ( n = 4). ( C ) IL-8 production post 24 h incubation was inhibited by Trametinib pretreatment ( n = 4). ( D ) CXCL8 mRNA expression was not influenced by Adezmapimod or SP600125 pretreatment in a concentration-dependent manner ( n = 4). Data are presented as mean +/− SEM, and each figure is representative from two independent experiments. Significant differences are determined using one-way ANOVA, followed by Tukey’s multiple comparisons test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; DMSO, dimethyl sulfoxide; Trametinib, MEK 1/2 inhibitor; Adezmapimod, <t>p38</t> <t>MAPK</t> inhibitor; SP600125, c-JUN N-terminal kinase inhibitor II; CAPE, NF-kβ inhibitor.
Anti Phospho P38 Mapk Thr180 Tyr182 3d7 Rabbit Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho p38 mapk thr180 tyr182 3d7 rabbit monoclonal antibody/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti phospho p38 mapk thr180 tyr182 3d7 rabbit monoclonal antibody - by Bioz Stars, 2024-10
86/100 stars
  Buy from Supplier
phospho p38 mapk thr180 tyr182  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc phospho p38 mapk thr180 tyr182
Representative maximum intensity projection images corresponding to panels E, F, H, I, J are shown in respectively. ( A ) The TRAK2 S84 phosphorylation site identified by mass spectrometry highlighted in an inset showing the CC1-box region of the TRAK2 coiled-coil prediction as in (top). ( B ) S84 conservation in TRAK2. ( C ) Representative maximum intensity projection images of cargo from cell lines expressing wt, S84A or S84E TRAK2. ( D ) Quantification of perinuclear cargo accumulation in cells as shown in (C) from two biological replicates. n(wt)=12; n(S84A)=12; p<0.0001 (two-tailed t-test, t=6.615, df=22); n(S84E)=12; p=0.5889 (two-tailed t-test, t=0.5485, df=22). ( E ) Quantification of perinuclear cargo accumulation in cells expressing synthetic cargo and TRAK2 following mock or JNK-in-8 (10 μM) treatment (3h) from three biological replicates. n(mock)=27; n(JNK-in-8)=27; p<0.0016 (two-tailed t-test, t=3.332, df=52). ( F ) Quantification of perinuclear cargo accumulation in cells expressing TRAK2 following RNAi treatment as indicated from two biological replicates. n(wt)=120; n(JNK1,p38δ)=29, n(JNK2,JNK3)=30; one-way ANOVA (F= 4.271, dFn =4, dFd =233) with a post hoc Dunnett’s test was used to determine significance. ( G ) Immunoblot analysis of untransduced whole cell lysate showing JNK- and <t>p38-kinase</t> activation in response to 3h oxidative treatments as indicated. ( H ) Quantification of mitochondrial clustering following oxidative treatment in untransduced cells from two biological replicates. n(mock)=63; n(arsenite)=18; p<0.0001 (two-tailed t-test, t=6.356, df=113); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.832, df=113). ( I ) Quantification of perinuclear cargo accumulation following oxidative treatment in cells expressing TRAK2 from two biological replicates. n(mock)=102; n(arsenite)=13; p<0.0001 (two-tailed t-test, t=6.436, df=79); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.336, df=79). ( J ) Quantification of perinuclear cargo accumulation following arsenite treatment in cells expressing wt or S84A TRAK2 from two biological replicates. Arsenite-induced accumulation was normalized to mock treated cells for both variants. n(treated wt)=18; n(treated S84A)=18; p=0.0003 (two-tailed t-test, t=3.996, df=34).
Phospho P38 Mapk Thr180 Tyr182, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho p38 mapk thr180 tyr182/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
phospho p38 mapk thr180 tyr182 - by Bioz Stars, 2024-10
86/100 stars
  Buy from Supplier
anti phospho p38 mapk thr180 tyr182  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc anti phospho p38 mapk thr180 tyr182
Representative maximum intensity projection images corresponding to panels E, F, H, I, J are shown in respectively. ( A ) The TRAK2 S84 phosphorylation site identified by mass spectrometry highlighted in an inset showing the CC1-box region of the TRAK2 coiled-coil prediction as in (top). ( B ) S84 conservation in TRAK2. ( C ) Representative maximum intensity projection images of cargo from cell lines expressing wt, S84A or S84E TRAK2. ( D ) Quantification of perinuclear cargo accumulation in cells as shown in (C) from two biological replicates. n(wt)=12; n(S84A)=12; p<0.0001 (two-tailed t-test, t=6.615, df=22); n(S84E)=12; p=0.5889 (two-tailed t-test, t=0.5485, df=22). ( E ) Quantification of perinuclear cargo accumulation in cells expressing synthetic cargo and TRAK2 following mock or JNK-in-8 (10 μM) treatment (3h) from three biological replicates. n(mock)=27; n(JNK-in-8)=27; p<0.0016 (two-tailed t-test, t=3.332, df=52). ( F ) Quantification of perinuclear cargo accumulation in cells expressing TRAK2 following RNAi treatment as indicated from two biological replicates. n(wt)=120; n(JNK1,p38δ)=29, n(JNK2,JNK3)=30; one-way ANOVA (F= 4.271, dFn =4, dFd =233) with a post hoc Dunnett’s test was used to determine significance. ( G ) Immunoblot analysis of untransduced whole cell lysate showing JNK- and <t>p38-kinase</t> activation in response to 3h oxidative treatments as indicated. ( H ) Quantification of mitochondrial clustering following oxidative treatment in untransduced cells from two biological replicates. n(mock)=63; n(arsenite)=18; p<0.0001 (two-tailed t-test, t=6.356, df=113); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.832, df=113). ( I ) Quantification of perinuclear cargo accumulation following oxidative treatment in cells expressing TRAK2 from two biological replicates. n(mock)=102; n(arsenite)=13; p<0.0001 (two-tailed t-test, t=6.436, df=79); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.336, df=79). ( J ) Quantification of perinuclear cargo accumulation following arsenite treatment in cells expressing wt or S84A TRAK2 from two biological replicates. Arsenite-induced accumulation was normalized to mock treated cells for both variants. n(treated wt)=18; n(treated S84A)=18; p=0.0003 (two-tailed t-test, t=3.996, df=34).
Anti Phospho P38 Mapk Thr180 Tyr182, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho p38 mapk thr180 tyr182/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
anti phospho p38 mapk thr180 tyr182 - by Bioz Stars, 2024-10
86/100 stars
  Buy from Supplier
p38 mapk phospho thr180 tyr182  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc p38 mapk phospho thr180 tyr182
Representative maximum intensity projection images corresponding to panels E, F, H, I, J are shown in respectively. ( A ) The TRAK2 S84 phosphorylation site identified by mass spectrometry highlighted in an inset showing the CC1-box region of the TRAK2 coiled-coil prediction as in (top). ( B ) S84 conservation in TRAK2. ( C ) Representative maximum intensity projection images of cargo from cell lines expressing wt, S84A or S84E TRAK2. ( D ) Quantification of perinuclear cargo accumulation in cells as shown in (C) from two biological replicates. n(wt)=12; n(S84A)=12; p<0.0001 (two-tailed t-test, t=6.615, df=22); n(S84E)=12; p=0.5889 (two-tailed t-test, t=0.5485, df=22). ( E ) Quantification of perinuclear cargo accumulation in cells expressing synthetic cargo and TRAK2 following mock or JNK-in-8 (10 μM) treatment (3h) from three biological replicates. n(mock)=27; n(JNK-in-8)=27; p<0.0016 (two-tailed t-test, t=3.332, df=52). ( F ) Quantification of perinuclear cargo accumulation in cells expressing TRAK2 following RNAi treatment as indicated from two biological replicates. n(wt)=120; n(JNK1,p38δ)=29, n(JNK2,JNK3)=30; one-way ANOVA (F= 4.271, dFn =4, dFd =233) with a post hoc Dunnett’s test was used to determine significance. ( G ) Immunoblot analysis of untransduced whole cell lysate showing JNK- and <t>p38-kinase</t> activation in response to 3h oxidative treatments as indicated. ( H ) Quantification of mitochondrial clustering following oxidative treatment in untransduced cells from two biological replicates. n(mock)=63; n(arsenite)=18; p<0.0001 (two-tailed t-test, t=6.356, df=113); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.832, df=113). ( I ) Quantification of perinuclear cargo accumulation following oxidative treatment in cells expressing TRAK2 from two biological replicates. n(mock)=102; n(arsenite)=13; p<0.0001 (two-tailed t-test, t=6.436, df=79); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.336, df=79). ( J ) Quantification of perinuclear cargo accumulation following arsenite treatment in cells expressing wt or S84A TRAK2 from two biological replicates. Arsenite-induced accumulation was normalized to mock treated cells for both variants. n(treated wt)=18; n(treated S84A)=18; p=0.0003 (two-tailed t-test, t=3.996, df=34).
P38 Mapk Phospho Thr180 Tyr182, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p38 mapk phospho thr180 tyr182/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
p38 mapk phospho thr180 tyr182 - by Bioz Stars, 2024-10
86/100 stars
  Buy from Supplier
phospho p38 mapk antibody thr180 tyr182 d3f9  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc phospho p38 mapk antibody thr180 tyr182 d3f9
Representative maximum intensity projection images corresponding to panels E, F, H, I, J are shown in respectively. ( A ) The TRAK2 S84 phosphorylation site identified by mass spectrometry highlighted in an inset showing the CC1-box region of the TRAK2 coiled-coil prediction as in (top). ( B ) S84 conservation in TRAK2. ( C ) Representative maximum intensity projection images of cargo from cell lines expressing wt, S84A or S84E TRAK2. ( D ) Quantification of perinuclear cargo accumulation in cells as shown in (C) from two biological replicates. n(wt)=12; n(S84A)=12; p<0.0001 (two-tailed t-test, t=6.615, df=22); n(S84E)=12; p=0.5889 (two-tailed t-test, t=0.5485, df=22). ( E ) Quantification of perinuclear cargo accumulation in cells expressing synthetic cargo and TRAK2 following mock or JNK-in-8 (10 μM) treatment (3h) from three biological replicates. n(mock)=27; n(JNK-in-8)=27; p<0.0016 (two-tailed t-test, t=3.332, df=52). ( F ) Quantification of perinuclear cargo accumulation in cells expressing TRAK2 following RNAi treatment as indicated from two biological replicates. n(wt)=120; n(JNK1,p38δ)=29, n(JNK2,JNK3)=30; one-way ANOVA (F= 4.271, dFn =4, dFd =233) with a post hoc Dunnett’s test was used to determine significance. ( G ) Immunoblot analysis of untransduced whole cell lysate showing JNK- and <t>p38-kinase</t> activation in response to 3h oxidative treatments as indicated. ( H ) Quantification of mitochondrial clustering following oxidative treatment in untransduced cells from two biological replicates. n(mock)=63; n(arsenite)=18; p<0.0001 (two-tailed t-test, t=6.356, df=113); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.832, df=113). ( I ) Quantification of perinuclear cargo accumulation following oxidative treatment in cells expressing TRAK2 from two biological replicates. n(mock)=102; n(arsenite)=13; p<0.0001 (two-tailed t-test, t=6.436, df=79); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.336, df=79). ( J ) Quantification of perinuclear cargo accumulation following arsenite treatment in cells expressing wt or S84A TRAK2 from two biological replicates. Arsenite-induced accumulation was normalized to mock treated cells for both variants. n(treated wt)=18; n(treated S84A)=18; p=0.0003 (two-tailed t-test, t=3.996, df=34).
Phospho P38 Mapk Antibody Thr180 Tyr182 D3f9, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho p38 mapk antibody thr180 tyr182 d3f9/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
phospho p38 mapk antibody thr180 tyr182 d3f9 - by Bioz Stars, 2024-10
86/100 stars
  Buy from Supplier

Image Search Results


CXCL8 mRNA expression and IL-8 production by P. intermedia supernatants might be induced through transduction via ERK 1/2. ( A ) Inhibition of CXCL8 mRNA expression with dimethyl sulfoxide, Trametinib, Adezmapimod, SP600125, and caffeic acid phenethyl ester at a concentration of 10 μM was analyzed using real-time RT-PCR post 4 h incubation ( n = 4). ( B ) CXCL8 mRNA expression was inhibited by Trametinib pretreatment in a concentration-dependent manner ( n = 4). ( C ) IL-8 production post 24 h incubation was inhibited by Trametinib pretreatment ( n = 4). ( D ) CXCL8 mRNA expression was not influenced by Adezmapimod or SP600125 pretreatment in a concentration-dependent manner ( n = 4). Data are presented as mean +/− SEM, and each figure is representative from two independent experiments. Significant differences are determined using one-way ANOVA, followed by Tukey’s multiple comparisons test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; DMSO, dimethyl sulfoxide; Trametinib, MEK 1/2 inhibitor; Adezmapimod, p38 MAPK inhibitor; SP600125, c-JUN N-terminal kinase inhibitor II; CAPE, NF-kβ inhibitor.

Journal: Antibiotics

Article Title: Clarithromycin Modulates Neutrophilic Inflammation Induced by Prevotella intermedia in Human Airway Epithelial Cells

doi: 10.3390/antibiotics13090909

Figure Lengend Snippet: CXCL8 mRNA expression and IL-8 production by P. intermedia supernatants might be induced through transduction via ERK 1/2. ( A ) Inhibition of CXCL8 mRNA expression with dimethyl sulfoxide, Trametinib, Adezmapimod, SP600125, and caffeic acid phenethyl ester at a concentration of 10 μM was analyzed using real-time RT-PCR post 4 h incubation ( n = 4). ( B ) CXCL8 mRNA expression was inhibited by Trametinib pretreatment in a concentration-dependent manner ( n = 4). ( C ) IL-8 production post 24 h incubation was inhibited by Trametinib pretreatment ( n = 4). ( D ) CXCL8 mRNA expression was not influenced by Adezmapimod or SP600125 pretreatment in a concentration-dependent manner ( n = 4). Data are presented as mean +/− SEM, and each figure is representative from two independent experiments. Significant differences are determined using one-way ANOVA, followed by Tukey’s multiple comparisons test. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; DMSO, dimethyl sulfoxide; Trametinib, MEK 1/2 inhibitor; Adezmapimod, p38 MAPK inhibitor; SP600125, c-JUN N-terminal kinase inhibitor II; CAPE, NF-kβ inhibitor.

Article Snippet: The following antibodies were supplied by Cell Signaling Technology (Danvers, MA, USA): anti-p44/42 MAPK (Erk1/2) antibody (#9102), anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (#9101L), anti-p38 MAPK antibody (#9212), anti-Phospho-p38 MAPK (Thr180/Tyr182) (3D7) rabbit monoclonal antibody (mAb) (#9215), anti-stress-activated protein kinase (SAPK)/JNK antibody (#9252), anti-phospho-SAPK/JNK (Thr183/Tyr185) antibody (#9251), anti-I-kappa-B-alpha (IkBa) (44D4) rabbit mAb (#4812), anti-Phospho-IkBa (Ser32) (14D4) rabbit mAb (#2859), and Erk3 antibody (#4067).

Techniques: Expressing, Transduction, Inhibition, Concentration Assay, Quantitative RT-PCR, Incubation

Representative maximum intensity projection images corresponding to panels E, F, H, I, J are shown in respectively. ( A ) The TRAK2 S84 phosphorylation site identified by mass spectrometry highlighted in an inset showing the CC1-box region of the TRAK2 coiled-coil prediction as in (top). ( B ) S84 conservation in TRAK2. ( C ) Representative maximum intensity projection images of cargo from cell lines expressing wt, S84A or S84E TRAK2. ( D ) Quantification of perinuclear cargo accumulation in cells as shown in (C) from two biological replicates. n(wt)=12; n(S84A)=12; p<0.0001 (two-tailed t-test, t=6.615, df=22); n(S84E)=12; p=0.5889 (two-tailed t-test, t=0.5485, df=22). ( E ) Quantification of perinuclear cargo accumulation in cells expressing synthetic cargo and TRAK2 following mock or JNK-in-8 (10 μM) treatment (3h) from three biological replicates. n(mock)=27; n(JNK-in-8)=27; p<0.0016 (two-tailed t-test, t=3.332, df=52). ( F ) Quantification of perinuclear cargo accumulation in cells expressing TRAK2 following RNAi treatment as indicated from two biological replicates. n(wt)=120; n(JNK1,p38δ)=29, n(JNK2,JNK3)=30; one-way ANOVA (F= 4.271, dFn =4, dFd =233) with a post hoc Dunnett’s test was used to determine significance. ( G ) Immunoblot analysis of untransduced whole cell lysate showing JNK- and p38-kinase activation in response to 3h oxidative treatments as indicated. ( H ) Quantification of mitochondrial clustering following oxidative treatment in untransduced cells from two biological replicates. n(mock)=63; n(arsenite)=18; p<0.0001 (two-tailed t-test, t=6.356, df=113); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.832, df=113). ( I ) Quantification of perinuclear cargo accumulation following oxidative treatment in cells expressing TRAK2 from two biological replicates. n(mock)=102; n(arsenite)=13; p<0.0001 (two-tailed t-test, t=6.436, df=79); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.336, df=79). ( J ) Quantification of perinuclear cargo accumulation following arsenite treatment in cells expressing wt or S84A TRAK2 from two biological replicates. Arsenite-induced accumulation was normalized to mock treated cells for both variants. n(treated wt)=18; n(treated S84A)=18; p=0.0003 (two-tailed t-test, t=3.996, df=34).

Journal: bioRxiv

Article Title: A molecular switch for stress-induced activation of retrograde mitochondrial transport

doi: 10.1101/2024.09.13.612963

Figure Lengend Snippet: Representative maximum intensity projection images corresponding to panels E, F, H, I, J are shown in respectively. ( A ) The TRAK2 S84 phosphorylation site identified by mass spectrometry highlighted in an inset showing the CC1-box region of the TRAK2 coiled-coil prediction as in (top). ( B ) S84 conservation in TRAK2. ( C ) Representative maximum intensity projection images of cargo from cell lines expressing wt, S84A or S84E TRAK2. ( D ) Quantification of perinuclear cargo accumulation in cells as shown in (C) from two biological replicates. n(wt)=12; n(S84A)=12; p<0.0001 (two-tailed t-test, t=6.615, df=22); n(S84E)=12; p=0.5889 (two-tailed t-test, t=0.5485, df=22). ( E ) Quantification of perinuclear cargo accumulation in cells expressing synthetic cargo and TRAK2 following mock or JNK-in-8 (10 μM) treatment (3h) from three biological replicates. n(mock)=27; n(JNK-in-8)=27; p<0.0016 (two-tailed t-test, t=3.332, df=52). ( F ) Quantification of perinuclear cargo accumulation in cells expressing TRAK2 following RNAi treatment as indicated from two biological replicates. n(wt)=120; n(JNK1,p38δ)=29, n(JNK2,JNK3)=30; one-way ANOVA (F= 4.271, dFn =4, dFd =233) with a post hoc Dunnett’s test was used to determine significance. ( G ) Immunoblot analysis of untransduced whole cell lysate showing JNK- and p38-kinase activation in response to 3h oxidative treatments as indicated. ( H ) Quantification of mitochondrial clustering following oxidative treatment in untransduced cells from two biological replicates. n(mock)=63; n(arsenite)=18; p<0.0001 (two-tailed t-test, t=6.356, df=113); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.832, df=113). ( I ) Quantification of perinuclear cargo accumulation following oxidative treatment in cells expressing TRAK2 from two biological replicates. n(mock)=102; n(arsenite)=13; p<0.0001 (two-tailed t-test, t=6.436, df=79); n(peroxide)=13; p<0.0001 (two-tailed t-test, t=7.336, df=79). ( J ) Quantification of perinuclear cargo accumulation following arsenite treatment in cells expressing wt or S84A TRAK2 from two biological replicates. Arsenite-induced accumulation was normalized to mock treated cells for both variants. n(treated wt)=18; n(treated S84A)=18; p=0.0003 (two-tailed t-test, t=3.996, df=34).

Article Snippet: The following primary antibodies were used: GFP (CST, 2555S), RFP (Proteintech, 6g6), KIF5B (abcam, ab167429), DHC1 (Santa Cruz Biotechnology, sc-514579), p150 (BD Biosciences, 610473), GAPDH (CST, 2118S), DIC (Sigma-Aldrich, MAB1618), p50 (BD Biosciences, 611002), SAPK/JNK (CST, 9252S), Phospho-SAPK/JNK (Thr183/Tyr185) (CST, 9251S), p38 MAPK (CST, 9212S), Phospho-p38 MAPK (Thr180/Tyr182) (CST, 9211S), O-GlcNAc [RL2] (abcam, ab2739), p38δ MAPK (CST, 2308T).

Techniques: Mass Spectrometry, Expressing, Two Tailed Test, Western Blot, Activation Assay